RxDoctor Payments Data

Rebecca Hennessy, MD

Family Medicine · Seymour, INNPI 1669828737

Payments from drug & device makers

$4,710in general payments, 2019–2025

Across 292 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$893
  • Lilly USA, LLC$862
  • GSK$431
  • Novartis$312
  • Boehringer Ingelheim$270
  • Pfizer$269
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,67299%
  • Education$381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,710 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$3,649
Medicare patients
79
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin121$143,773
MounjaroTirzepatide111$127,201
Trelegy ElliptaFluticasone/Umeclidin/Vilanter112$99,473
TrulicityDulaglutide56$74,972
OzempicSemaglutide55$71,003
EliquisApixaban65$66,203
FarxigaDapagliflozin Propanediol32$40,170
MyrbetriqMirabegron34$33,254
LinzessLinaclotide28$32,770
Trijardy XrEmpaglifloz/Linaglip/Metformin15$21,486
Synjardy XrEmpagliflozin/Metformin Hcl14$19,137
EntrestoSacubitril/Valsartan11$11,799
PremarinEstrogens, Conjugated11$4,863
Atorvastatin Calcium489$2,902
Albuterol Sulfate HfaAlbuterol Sulfate74$2,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$862$202,173167 claims
Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr$270$184,395150 claims
GSKTrelegy Ellipta$431$99,473112 claims
PfizerEliquis, Premarin$269$71,06676 claims
Novo NordiskOzempic$266$71,00355 claims
AstraZenecaFarxiga$251$40,17032 claims
AbbVieLinzess, Synthroid$893$34,79065 claims
Astellas Pharma US IncMyrbetriq$72$33,25434 claims
NovartisEntresto$312$11,79911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Seymour

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →